These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 17391705

  • 1. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O, Kieseier BC, Hartung HP.
    J Neurol Sci; 2007 Aug 15; 259(1-2):27-37. PubMed ID: 17391705
    [Abstract] [Full Text] [Related]

  • 2. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O, Stüve O, Archelos JJ, Hartung HP.
    J Neurol Sci; 2005 Jun 15; 233(1-2):173-7. PubMed ID: 15949504
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May 15; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA, Agius MA.
    Neurology; 2004 Dec 28; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C, Bouhour F, Vukusic S.
    Rev Prat; 1999 Nov 01; 49(17):1882-9. PubMed ID: 10598505
    [Abstract] [Full Text] [Related]

  • 14. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH, Javed A.
    Curr Opin Ophthalmol; 2009 Nov 01; 20(6):476-81. PubMed ID: 19816177
    [Abstract] [Full Text] [Related]

  • 15. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B, Cepok S, Nessler S, Sommer N.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():23-8. PubMed ID: 11603112
    [Abstract] [Full Text] [Related]

  • 16. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J, Cristiano E.
    Medicina (B Aires); 2001 Sep 15; 61(4):470-80. PubMed ID: 11563177
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E, Vécsei L.
    Ideggyogy Sz; 2006 May 20; 59(5-6):156-62. PubMed ID: 16786710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.